Metraipolis › archive › dc_cce42f709d82
NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency — Europe PMC PMID:32744500
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32744500
- DOI
- 10.7554/elife.54993
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-07T21:14:35.793Z
- SHA-256 of the archived text
af7ad95995ea51cc226ca312079fa722aa594a76a65b67346e4f76439524defc- Stable URL of this page
https://metraipolis.com/documento/dc_cce42f709d82
How to cite
NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency — Europe PMC PMID:32744500 — Europe PMC (en), https://europepmc.org/article/MED/32744500 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_cce42f709d82 (Metraipolis archive dc_cce42f709d82, sha256 af7ad95995ea51cc226ca312079fa722aa594a76a65b67346e4f76439524defc)
BibTeX
@misc{dccce42f709d82,
title = {NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency — Europe PMC PMID:32744500},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32744500},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_cce42f709d82; sha256 af7ad95995ea51cc226ca312079fa722aa594a76a65b67346e4f76439524defc},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32744500. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The NuRD complex subunit CHD4 is essential for fusion-positive rhabdomyosarcoma (FP-RMS) survival, but the mechanisms underlying this dependency are not understood. Here, a NuRD-specific CRISPR screen demonstrates that FP-RMS is particularly sensitive to CHD4 amongst the NuRD members. Mechanistically, NuRD complex containing CHD4 localizes to super-enhancers where CHD4 generates a chromatin architecture permissive for the binding of the tumor driver and fusion protein PAX3-FOXO1, allowing downstream transcription of its oncogenic program. Moreover, CHD4 depletion removes HDAC2 from the chromatin, leading to an increase and spread of histone acetylation, and prevents the positioning of RNA Polymerase 2 at promoters impeding transcription initiation. Strikingly, analysis of genome-wide cancer dependency databases identifies CHD4 as a general cancer vulnerability. Our findings describe CHD4, a classically defined repressor, as positive regulator of transcription and super-enhancer accessibility as well as establish this remodeler as an unexpected broad tumor susceptibility and promising drug target for cancer therapy. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: eLife, 2020 (prima pubblicazione 2020-08-03). Identificativi: PMID 32744500 · PMCID PMC7438112 · DOI 10.7554/elife.54993. Parole chiave degli autori: Human; Rhabdomyosarcoma; Chromatin remodeling; Cancer Biology; Nurd; Chd4; Dna Accessibility; Super-enhancer. Descrittori MeSH principali: Gene Expression Regulation, Neoplastic. Pagina: https://europepmc.org/article/MED/32744500 — https://doi.org/10.7554/elife.54993. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-07T21:10:38.825Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.